S&P 500   3,320.08 (-0.16%)
DOW   29,173.00 (+0.04%)
QQQ   224.96 (+0.16%)
AAPL   323.19 (+1.24%)
FB   220.48 (+0.33%)
MSFT   167.25 (+0.32%)
GOOGL   1,486.69 (+0.13%)
AMZN   1,886.00 (+0.08%)
NVDA   255.07 (+0.87%)
BABA   217.95 (-0.54%)
MU   58.91 (-0.49%)
GE   11.77 (+0.00%)
TSLA   566.95 (-0.92%)
AMD   51.21 (-0.97%)
T   38.77 (+0.36%)
ACB   2.02 (-2.42%)
F   9.03 (-1.20%)
BAC   33.74 (-1.11%)
DIS   141.37 (-0.58%)
GILD   63.70 (-0.38%)
S&P 500   3,320.08 (-0.16%)
DOW   29,173.00 (+0.04%)
QQQ   224.96 (+0.16%)
AAPL   323.19 (+1.24%)
FB   220.48 (+0.33%)
MSFT   167.25 (+0.32%)
GOOGL   1,486.69 (+0.13%)
AMZN   1,886.00 (+0.08%)
NVDA   255.07 (+0.87%)
BABA   217.95 (-0.54%)
MU   58.91 (-0.49%)
GE   11.77 (+0.00%)
TSLA   566.95 (-0.92%)
AMD   51.21 (-0.97%)
T   38.77 (+0.36%)
ACB   2.02 (-2.42%)
F   9.03 (-1.20%)
BAC   33.74 (-1.11%)
DIS   141.37 (-0.58%)
GILD   63.70 (-0.38%)
S&P 500   3,320.08 (-0.16%)
DOW   29,173.00 (+0.04%)
QQQ   224.96 (+0.16%)
AAPL   323.19 (+1.24%)
FB   220.48 (+0.33%)
MSFT   167.25 (+0.32%)
GOOGL   1,486.69 (+0.13%)
AMZN   1,886.00 (+0.08%)
NVDA   255.07 (+0.87%)
BABA   217.95 (-0.54%)
MU   58.91 (-0.49%)
GE   11.77 (+0.00%)
TSLA   566.95 (-0.92%)
AMD   51.21 (-0.97%)
T   38.77 (+0.36%)
ACB   2.02 (-2.42%)
F   9.03 (-1.20%)
BAC   33.74 (-1.11%)
DIS   141.37 (-0.58%)
GILD   63.70 (-0.38%)
S&P 500   3,320.08 (-0.16%)
DOW   29,173.00 (+0.04%)
QQQ   224.96 (+0.16%)
AAPL   323.19 (+1.24%)
FB   220.48 (+0.33%)
MSFT   167.25 (+0.32%)
GOOGL   1,486.69 (+0.13%)
AMZN   1,886.00 (+0.08%)
NVDA   255.07 (+0.87%)
BABA   217.95 (-0.54%)
MU   58.91 (-0.49%)
GE   11.77 (+0.00%)
TSLA   566.95 (-0.92%)
AMD   51.21 (-0.97%)
T   38.77 (+0.36%)
ACB   2.02 (-2.42%)
F   9.03 (-1.20%)
BAC   33.74 (-1.11%)
DIS   141.37 (-0.58%)
GILD   63.70 (-0.38%)
Log in

NASDAQ:GLYC - GlycoMimetics Stock Price, Forecast & News

$4.65
-0.04 (-0.85 %)
(As of 01/24/2020 11:21 AM ET)
Today's Range
$4.62
Now: $4.65
$4.82
50-Day Range
$4.69
MA: $5.38
$6.16
52-Week Range
$2.64
Now: $4.65
$13.56
Volume1,029 shs
Average Volume222,755 shs
Market Capitalization$201.62 million
P/E RatioN/A
Dividend YieldN/A
Beta2.58
GlycoMimetics, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. The company's advanced drug candidate, rivipansel, is a pan-selectin antagonist, which is developed for the treatment of vaso-occlusive crisis in sickle cell disease and is in a Phase III clinical trial, conducted by its strategic collaboration with Pfizer Inc It is also developing uproleselan, an E-selectin antagonist that is evaluated in a Phase I/II clinical trial as a potential treatment for acute myeloid leukemia (AML), as well as Phase III trial to treat relapsed/refractory AML. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:GLYC
CUSIPN/A
Phone240-243-1201

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$4.76 per share

Profitability

Net Income$-48,270,000.00

Miscellaneous

Employees50
Market Cap$201.62 million
Next Earnings Date3/4/2020 (Estimated)
OptionableOptionable

Receive GLYC News and Ratings via Email

Sign-up to receive the latest news and ratings for GLYC and its competitors with MarketBeat's FREE daily newsletter.


GlycoMimetics (NASDAQ:GLYC) Frequently Asked Questions

What is GlycoMimetics' stock symbol?

GlycoMimetics trades on the NASDAQ under the ticker symbol "GLYC."

How were GlycoMimetics' earnings last quarter?

GlycoMimetics Inc (NASDAQ:GLYC) released its quarterly earnings data on Thursday, November, 7th. The biotechnology company reported ($0.31) EPS for the quarter, beating analysts' consensus estimates of ($0.39) by $0.08. View GlycoMimetics' Earnings History.

When is GlycoMimetics' next earnings date?

GlycoMimetics is scheduled to release their next quarterly earnings announcement on Wednesday, March 4th 2020. View Earnings Estimates for GlycoMimetics.

What price target have analysts set for GLYC?

6 brokerages have issued 12-month price objectives for GlycoMimetics' stock. Their forecasts range from $5.00 to $18.00. On average, they anticipate GlycoMimetics' share price to reach $9.25 in the next year. This suggests a possible upside of 98.9% from the stock's current price. View Analyst Price Targets for GlycoMimetics.

What is the consensus analysts' recommendation for GlycoMimetics?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GlycoMimetics in the last year. There are currently 3 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for GlycoMimetics.

Has GlycoMimetics been receiving favorable news coverage?

News articles about GLYC stock have been trending negative this week, InfoTrie reports. The research group identifies negative and positive media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. GlycoMimetics earned a media sentiment score of -2.8 on InfoTrie's scale. They also gave news stories about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for GlycoMimetics.

Who are some of GlycoMimetics' key competitors?

What other stocks do shareholders of GlycoMimetics own?

Who are GlycoMimetics' key executives?

GlycoMimetics' management team includes the folowing people:
  • Ms. Rachel K. King, Pres, CEO & Director (Age 60)
  • Mr. Brian M. Hahn, Sr. VP, CFO & Sec. (Age 45)
  • Dr. John L. Magnani, Sr. VP of Research, Chief Scientific Officer & Director (Age 66)
  • Dr. Helen M. Thackray, Sr. VP of Clinical Devel. & Chief Medical Officer (Age 51)
  • Mr. Henry Flanner, VP of Technical Operations

How do I buy shares of GlycoMimetics?

Shares of GLYC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is GlycoMimetics' stock price today?

One share of GLYC stock can currently be purchased for approximately $4.65.

How big of a company is GlycoMimetics?

GlycoMimetics has a market capitalization of $201.62 million. The biotechnology company earns $-48,270,000.00 in net income (profit) each year or ($1.18) on an earnings per share basis. GlycoMimetics employs 50 workers across the globe.View Additional Information About GlycoMimetics.

What is GlycoMimetics' official website?

The official website for GlycoMimetics is http://www.glycomimetics.com/.

How can I contact GlycoMimetics?

GlycoMimetics' mailing address is 9708 MEDICAL CENTER DRIVE, ROCKVILLE MD, 20850. The biotechnology company can be reached via phone at 240-243-1201 or via email at [email protected]


MarketBeat Community Rating for GlycoMimetics (NASDAQ GLYC)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  283 (Vote Outperform)
Underperform Votes:  247 (Vote Underperform)
Total Votes:  530
MarketBeat's community ratings are surveys of what our community members think about GlycoMimetics and other stocks. Vote "Outperform" if you believe GLYC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GLYC will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/24/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel